Ryerson, Lana Zhovtis et al "Reduced risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab extended interval dosing (EID): updated analysis of the TOUCH® Prescribing Program database (S26.006)." Neurology 92.15 Supplement (2019): S26.006. Web. 23 Jan. 2020.